AshionAnalytics's GEM Cancer Panel to Improve Patient Care
FREMONT, CA: Ashion Analytics, a CAP (College of American Pathologists) accredited and CLIA (Clinical Laboratory Improvement Amendments) certified clinical genomics testing laboratory, announces its product, Genomic Enabled Medicine (GEM) Cancer Panel, to aid doctors in treating cancer patients, reports PR Newswire.
The company’s GEM Cancer Panel furnishes vital interpreted information for physicians that helps in understanding a patient’s genomic profile changes and draft a therapeutic plan suited for them. Conditions such as refractory, rare and aggressive cancers can reap benefits from this approach. Concomitant analysis of germline DNA allows quick identification of true somatic alterations and enhances the likelihood of identifying tumor-specific variations with a higher accuracy allowing drug relationships to be solely based on tumor-specific alterations resulting in increased safe treatments.
The panel consists of 562 genes including coding regions for 540 genes, and non-coding regions for an additional 22 genes that are known to be structurally rearranged or altered in cancer. It captures copy number events and structural variations. Advanced annotation is combined with pharmacologic treatment options, thus producing a detailed genomic analysis of a patient’s cancer.
Ashion Analytics provides expanded whole exome sequencing with its GEM-GW test to support research studies and clinical trials. It includes analysis of copy number events and structural variation along with RNA sequencing. The company is providing a means to tap the information of human cancer genome for hospitals, universities, research and pharmaceutical customers.
"Our understanding of genomics today is fundamentally changing the way we view and treat cancer, and we believe the future holds even greater promise," says Michael Demeure, MD, MBA, EVP and GM, Ashion Analytics. "As a physician who continues to treat cancer patients, I see every day the critical need to develop better diagnostics as well as new, more effective, and less toxic treatment options. This unmet need drives all our efforts at Ashion Analytics."